Back to search
FDAFDA · Food and drugs·Recall number D-0304-2025

Tolterodine Tartrate Extended-Release Capsules, 2 mg, 30 Capsules (3 x 10) Unit Dose carton, Rx only, Packaged and Distributed by: Major Pharmaceuticals, Indianapolis, IN 46268 USA, NDC 0904-6592-04.

Published April 9, 2025 · Recall initiated: March 4, 2025

Summary

FDA records drug Class III recall D-0304-2025, published April 9, 2025 and initiated March 4, 2025. Recalling firm: The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories; Status: Terminated; Reported quantity: 224 cartons; Lot: Lot# T05393, Exp. Date: 09/30/2025. Class III means the product is not likely to cause adverse health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Dissolution Specifications: Out of specification results obtained during routine stability testing for dissolution.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories
Distributor
Nationwide in the USA
Lot
Lot# T05393, Exp. Date: 09/30/2025
Risk classification
Class III
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Tolterodine Tartrate Extended-Release Capsules, 2 mg, 30 Capsules (3 x 10) Unit Dose carton, Rx only, Packaged and Distributed by: Major Pharmaceuticals, Indianapolis, IN 46268 USA, NDC 0904-6592-04. recalled?

Yes. FDA published recall D-0304-2025 on April 9, 2025. Reported hazard: Failed Dissolution Specifications: Out of specification results obtained during routine stability testing for dissolution.

What should I do if I have this product?

Voluntary: Firm initiated · Letter